Skip to main content

Table 2 Efficacy of methylphenidate on the simplified Conners’ rating scale and other secondary endpoints

From: The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial

 

Within-patient difference

MPD effect

 

MPD

Placebo

 

Parent’s version (Main endpoint)

-5.7 (-7.3, -4.1)

-1.8 (-3.4, -0.1)

-3.9 (-6.1, -1.7)

Teacher’s version

-3.5 (-5.8, -1.2)

-1.6 (-3.8, 0.6)

-1.9 (-5.0, 1.1)*

CDRs

-2.9 (-5.0, -0.9)

-1.9 (-4.0, 0.2)

-1.1 (-4.0, 1,8)

CDI

-2.1 (-3.9, -0.4)

-1.9 (-3.7, -0.1)

-0.2 (-2.7, 2.3)

STAIc-state

-3.2 (-5.1, -1.2)

-1.9 (-3.8, 0.1)

-1.3 (-4.0, 1.4)

STAIc-trait

-3.1 (-5.2, -1.0)

-2.7 (-4.8, -0.6)

-0.3 (-3.3, 2.6)

  1. *NS, 50% of data were missing.
  2. Mean variation (95% confidence limits).